A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model

The blockade of programmed cell death-1 (PD1) and its ligand PDL1 has been proven to be a successful immunotherapy against several cancers. Similar to cancer, PD1 contributes to the establishment of several chronic infectious diseases, including malaria. While monoclonal antibodies (mAbs) targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Phares, Timothy W., Kotraiah, Vinayaka, Karunarathne, Deshapriya S., Huang, Jing, Browne, Cecille D., Buontempo, Peter, Mansour, Marc, Noe, Amy R., Wykes, Michelle N., Pannucci, James, Tsuji, Moriya, Gutierrez, Gabriel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363839/
https://www.ncbi.nlm.nih.gov/pubmed/32733457
http://dx.doi.org/10.3389/fimmu.2020.01377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363839/
https://www.ncbi.nlm.nih.gov/pubmed/32733457
http://dx.doi.org/10.3389/fimmu.2020.01377

Ejemplares similares